The listed biotech has a pipeline of RNA-based drugs to treat rare conditions such as blinding eye diseases and polycystic kidney disease.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. PYC Therapeutics Limited ( (AU:PYC)) just ...

In the second chunky biotech raising so far this year, PYC Therapeutics is seeking $650 million via a placement and ... Read More The post Health Check: PYC Therapeutics kicks off monster $650m ...

PYC Therapeutics Limited ( (AU:PYC)) has issued an announcement. PYC Therapeutics Limited has issued 2.5 million unlisted employee options under its employee incentive scheme, effective 5 January 2026 ...

Zero-debt allows substantial financial flexibility, especially for small-cap companies like Physiomics Plc (LON:PYC), as the company does not have to adhere to strict debt covenants. However, it also ...

The last three months have been tough on PYC Therapeutics Limited (ASX:PYC) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the returns ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics Limited has announced a significant breakthrough in treating Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PYC Therapeutics raised AU$40 million of an anticipated AU$74 million (US$48.6 million) capital raise to advance three candidates, including lead candidate VP-001, which could potentially be the first ...